Blog

JPM 2026 is expected to double‑down on AI, capital discipline, and late‑stage “de‑risked” assets, with oncology, neuro and AI‑enabled platforms at the center of the narrative.​1. AI everywhere, but judged on ROI Conference materials and satellite briefings flag AI‑driven R&amp;D, diagnostics, and operationsas a defining theme, not a side track.​ VCs expect 2026 funding to favor AI that clearly cuts cost, boosts productivity, or enables new economics (e.g. payor‑facing analytics, revenue‑cycle and admin AI, ambient documentation) rather than generic “AI for X” point tools.​ 2. Therapeutic focus: oncology, neuro, hematology JPM 2026 agendas and attendee guides emphasize oncology, neuropsychiatry/neurology, and hematology as the leading therapeutic spotlight areas.​ Expect significant attention to late‑stage and commercial‑stage assets in complex cancers, schizophrenia/bipolar, neurodegeneration, and rare hematologic diseases, often paired with biomarker and companion diagnostic plays.​ 3. Biotech and “TechBio” reset, not rebound Preview pieces suggest a continued bifurcation: high‑quality, data‑rich “TechBio” platforms and validated assets re‑rate, while sub‑scale discovery stories struggle to raise on acceptable terms.​ Gene/cell therapy, precision oncology, and platform biotechs will be framed around capital efficiency, partnering, and risk‑sharing structures rather than pure “moonshot” narratives.​ 4. Digital health, medtech and IPO/M&amp;A dynamics Digital health and medtech sessions are expected to focus on:Profitability and unit‑economic proof for care‑delivery and virtual models. Device‑plus‑software and wearable / monitoring platforms with real‑world data moats.​2026 is widely framed as a “clearing event” year: a thin IPO window with a handful of scaled, profitable issuers, alongside more take‑privates, roll‑ups and strategic acquisitions, especially in AI and tech‑enabled services.​ 5. Policy, regulation and trust in AI Agendas and commentary highlight regulatory and policy panels around FDA modernization, AI/ML frameworks, privacy, and global market access as core content rather than side events.​ Expect heavy discussion of algorithmic bias, safety, explainability, and reimbursement for AI‑enabled products, as payors and regulators push for demonstrable clinical and economic value.​ 6. Health system strategy and care models Post‑2025 takeaways indicate providers coming into JPM 2026 focused on:Shifting volume to outpatient, home‑based and lower‑cost settings. Using AI, automation and new contracting models to manage labor, margin pressure and chronic care at scale.​ Partnerships between big tech, payors, and IDNs around data, AI and “care‑anywhere” models are expected to be key deal and JV storylines during the week.<a data-mce-href="https://www.jpmorgan.com/about-us/events-conferences/health-care-conference" href="https://www.jpmorgan.com/about-us/events-conferences/health-care-conference" title="https://www.jpmorgan.com/about-us/events-conferences/health-care-conference" target="_blank" rel="noopener" data-mce-selected="inline-boundary">https://www.jpmorgan.com/about-us/events-conferences/health-care-conference</a>

J.P. Morgan Annual Healthcare Conference 2026: Key predictions and expected themes

Across 2025, HealthTech and MedTech M&amp;A multiples have clustered around x4 to x6 revenue for most assets, with clear premiums where specific strategic and financial variables line up.​Company quality and financial profileStage, size and profitability – Later‑stage, scaled assets with positive EBITDA and &gt;£20–30m revenue command higher revenue and EBITDA multiples than early‑stage or sub‑scale startups, which often compress to 3–4x unless strategically unique.​Revenue growth and visibility – Sustained organic growth &gt;25–30% with contracted or recurring components (SaaS, subscription, consumables) supports upper‑quartile valuations; flat or volatile revenue pushes deals toward the lower end of the range.​Margin structure and unit economics – High gross margins (70%+ for software / digital; &gt;60% for premium MedTech) and attractive LTV/CAC or payback periods justify premium pricing versus hardware‑heavy or low‑margin, labour‑intensive models.​Strategic fit, differentiation and riskIP, clinical evidence and “technology moat” – Proprietary algorithms, protected devices or clinically validated platforms (e.g. RCTs, real‑world outcomes, reimbursement codes) underpin defensibility and can lift valuations into 6–8x+ revenue for top assets.​Regulatory position and market access – Clean MDR / IVDR or FDA status, clear SaMD classification, and established reimbursement (e.g. procedure codes, DiGA‑style listing, HTA support) reduce execution risk and support higher multiples than assets still pre‑clearance.​Alignment with value‑based care and system priorities – Solutions that demonstrably reduce cost or improve outcomes in priority areas (chronic disease, hospital at home, productivity, workforce shortages) attract strategic buyers and 5.5–7x+ revenue ranges.​ Sector and macro positioningExposure to AI, data and infrastructure – AI‑first diagnostics, workflow automation, and data or infrastructure plays (EHDS‑aligned, interoperability, RCM, analytics) are repeatedly cited as earning the highest HealthTech and MedTech premiums in 2025.​Sub‑sector and demand tailwinds – Segments like value‑based care platforms, telehealth, robotics, advanced imaging, and minimally invasive devices benefit from ageing populations and chronic disease trends, sustaining 6–8x+ revenue for best‑in‑class companies.​Deal dynamics and capital marketsBuyer universe and competitive tension – Multiples spike where there is strong interest from both strategics and PE with “dry powder”, especially in auction processes for scarce assets; bilateral or distressed situations clear at discounts.​Funding environment, rates and exit options – Higher interest rates, tariff and policy uncertainty, and IPO market weakness have kept many 2025 deals disciplined, but easing rates and clearer EU AI/EHDS rules are starting to stabilise or lift MedTech and digital‑health valuations in H2 2025.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

10 Key Variables driving HealthTech and MedTech M&A valuation multiples throughout 2025

The biggest European MedTech developments this week centre on EU regulatory reform under MDR/IVDR and fresh late‑stage capital aimed at European MedTech scale‑ups.​EU MDR/IVDR revision and simplificationThe European Commission has proposed a targeted simplification of the Medical Device and IVD Regulations to make conformity assessment faster, less bureaucratic and more innovation‑friendly, while maintaining safety.​ Changes focus on digitalising procedures, improving EUDAMED, easing the transition for “legacy” devices and addressing bottlenecks caused by limited notified‑body capacity, after strong industry pressure that current rules were stifling MedTech innovation.​ Capital for MedTech and digital health scale‑ups A €150m co‑investment vehicle (50% European Investment Bank, 50% Angelini Ventures) has been confirmed to finance European biotech, MedTech and digital health companies at market‑launch/scale‑up stage, directly targeting the Series‑B “valley of death”.​ Weekly funding analyses show Europe attracting multi‑billion‑euro healthtech investment in 2025, with capital concentrating in AI‑enabled diagnostics, digital infrastructure and value‑based care platforms that can benefit from clearer EU rules and reimbursement pathways.​ MDR certification and market access milestones Shape Memory Medical secured EU MDR Class III certification for its IMPEDE embolisation plug family, underscoring that complex interventional devices can clear the stricter regime and secure long‑term EU market access.​Commentators note that MDR certifications like this increasingly rely on robust real‑world performance data and registries, signalling that post‑market evidence has become a decisive competitive asset for European MedTech players.European HealthTech this week is dominated by EU‑level policy moves around data and AI plus continued capital formation and grant activity supporting digital health scale‑ups.​EU health data and AI frameworkThe Regulation establishing the European Health Data Space (EHDS) is now in force, creating a harmonised framework for primary and secondary use of electronic health data and enabling cross‑border sharing via the MyHealth@EU infrastructure.​In parallel, the Commission’s Digital Omnibus and AI‑focused health package aim to align AI Act obligations with MDR/IVDR and simplify digital and AI rules for health technologies, reducing fragmentation for HealthTech builders.​Funding and scale‑up capitalA €150m co‑investment vehicle from the European Investment Bank and Angelini Ventures has been confirmed to back 7–10 European biotech, MedTech and digital health companies at market‑launch/scale‑up stage, directly targeting the Series‑B funding gap.​ Broader 2025 funding analyses show multi‑billion‑euro flows into European digital health, with around 60% of recent capital going to AI‑driven ventures and infrastructure platforms benefiting from EHDS and clearer reimbursement paths (e.g. DiGA‑style schemes).​ Grants, calls and ecosystem activity EIT Health’s 2025 Flagships call is directing funding to patient‑centred digital health solutions and evidence‑generation projects that help CE‑marked digital medical devices enter new EU markets.​ EU‑level programmes like EU4Health, Digital Europe and Horizon Europe continue to allocate substantial non‑dilutive funding to digital health infrastructure, AI and interoperability, with new maps and guidance published to help innovators navigate these instruments.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email<a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title=" lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener"> lloyd@nelsonadvisors.co.uk</a>

This Week in European HealthTech and MedTech: 23rd December 2025

The European financial advisory landscape for Healthcare Technology (HealthTech) and Medical Technology (MedTech) is currently navigating a period of profound structural transformation. For the better part of three decades, the provision of merger and acquisition (M&amp;A) advisory services was the exclusive domain of career financiers, individuals whose expertise lay in financial engineering, balance sheet restructuring, and capital markets access, but who frequently lacked direct operational experience in the industries they served.&nbsp; &nbsp;&nbsp; As the European digital health sector matures, transitioning from a nascent collection of startups into a critical component of national infrastructure, a new paradigm is emerging: the rise of the "Founder Banker." &nbsp;&nbsp; This report provides an analysis of this new generation of advisors. These are individuals who have successfully built, scaled and exited their own ventures before transitioning into advisory roles. They bring a distinct value proposition characterised by "operational empathy," deep technical fluency and an ability to bridge the widening gap between the metrics of the digital economy (SaaS) and the regulatory realities of healthcare (clinical validation). &nbsp;&nbsp; The analysis reveals a marked bifurcation in the market structure. While "Mega-Cap Generalists" like Goldman Sachs and J.P. Morgan continue to dominate multi-billion dollar transformative deals, increasingly bolstering their ranks with medical doctors (MDs) to gain scientific credibility, a vibrant ecosystem of "Specialist Boutiques" has emerged to serve the mid-market.&nbsp; Firms such as Nelson Advisors in the UK, Clipperton in France, and ConAlliance in the DACH region are redefining how value is articulated in a market constrained by high interest rates and regulatory headwinds like the EU AI Act. &nbsp;&nbsp; This report outlines the biographies, strategies and market impact of these founder led firms. It explores how their operational DNA influences deal structuring, valuation methodologies and the navigation of complex regulatory frameworks. Furthermore, it posits that the "Founder Banker" model is not merely a niche trend but a necessary evolution in an industry where the complexity of the underlying assets, AI algorithms, digital therapeutics and interconnected care platforms, exceeds the analytical capabilities of generalist finance.Source: <a href="https://www.healthcare.digital/single-post/the-rise-of-the-founder-banker-advising-european-healthtech-and-medtech">https://www.healthcare.digital/single-post/the-rise-of-the-founder-banker-advising-european-healthtech-and-medtech</a>

'Founder Bankers' advising European HealthTech and MedTech

The biggest European MedTech developments this week centre on the EU’s proposed overhaul of MDR/IVDR, a broader Commission health package to boost innovation and resilience, and continued capital formation for MedTech and digital health scale‑ups. Together these moves signal a more innovation‑friendly regulatory path and fresh growth funding for European MedTech heading into 2026.​MDR/IVDR targeted revision The European Commission has proposed a targeted simplification of the Medical Devices Regulation (MDR) and In Vitro Diagnostics Regulation (IVDR) to make rules easier, faster and more effective while maintaining high patient safety.​ MedTech Europe welcomed the proposal as a “long‑awaited and necessary step” to fix parts of the system that are not working for patients, innovators and providers, highlighting the need to reduce bureaucracy and restore Europe’s competitiveness in MedTech.​ Wider EU health package The MDR/IVDR revision forms part of a broader Commission package of new measures aimed at creating an innovative and resilient health sector that delivers better outcomes across the EU.​ This package sits alongside initiatives like the Digital Omnibus and other digitalisation efforts, signalling a coordinated push to streamline health regulations, support data‑driven technologies and modernise procedures for medical technologies.​ Digital and AI regulatory alignment The Digital Omnibus proposals seek to rationalise how AI Act obligations interact with MDR/IVDR, as well as streamline data protection, cybersecurity and reporting frameworks that directly affect MedTech companies.​ Legal and policy analyses point out that this combination of Digital Omnibus and MDR/IVDR revision is intended to reduce regulatory fragmentation and over‑regulation that have been criticised for slowing innovation in European MedTech.​ Capital formation and scale‑up funding A €150 million co‑investment agreement between the European Investment Bank and Angelini Ventures, with €75 million from each, has been confirmed to finance European startups in biotechnology, MedTech and digital health.​ The vehicle aims to support seven to ten innovative European companies at market‑launch stage, directly addressing the late‑stage “valley of death” for MedTech and digital health scale‑ups.​ Operational and implementation themes Ongoing work around EUDAMED and MDR/IVDR implementation, including stepwise activation of database modules and extended transition periods for legacy devices, continues to shape day‑to‑day compliance planning for manufacturers and hospitals.​ These implementation changes are designed to prevent supply disruption while collecting better data on device availability, which will inform further tweaks to the regulatory framework through 2025–2026.&gt;&gt;&gt;European HealthTech this week is defined by the Commission’s new health package and EHDS rollout, ongoing EU‑level digital health strategy, and continued investor focus on AI‑driven platforms and infrastructure. These themes reinforce a policy and funding environment that is increasingly supportive of data‑intensive HealthTech business models across the continent.​EU health package and digitalisationThe European Commission has proposed new measures to create an innovative and resilient health sector that “delivers for patients”, with digitalisation and data use as central pillars.​ This sits alongside broader EU digital health work, where priorities include secure cross‑border access to health data, shared data infrastructure for personalised medicine, and citizen empowerment with digital tools.​ European Health Data Space (EHDS) Regulation (EU) 2025/327 formally establishing the European Health Data Space is now in force, laying down obligations for primary and secondary use of electronic health data across public and private actors.​ EHDS is expected to be structurally disruptive for HealthTech, enabling new business models in data‑driven care, research and AI, supported by a central MyHealth@EU interoperability platform for cross‑border EHR and e‑prescription exchange.​ EU funding and grant environment The EU has earmarked significant funding for digital health through programmes such as EU4Health and Digital Europe, with a strong focus on AI, interoperability, cybersecurity and cross‑border digital infrastructure.​ Specialist round‑ups highlight EU grants in 2025 targeting AI in healthcare, mental health and pandemic preparedness, providing non‑dilutive capital that can be blended with VC rounds for HealthTech startups.​ Market and investment signals Analyses of the 2025 HealthTech investment landscape show Europe attracting multi‑billion euro funding with healthtech among the most funded sectors, helped by EHDS and supportive digital policies.​ Funding commentators emphasise that roughly the majority of recent digital health capital is flowing into AI‑driven ventures and infrastructure plays, with reimbursement frameworks like DiGA and similar schemes in France and the Nordics seen as critical for scale‑up.​ Ecosystem initiatives and calls EIT Health’s 2025 “Digital Transformation of Healthcare” flagship call is directing money toward patient‑centred digital health solutions and evidence generation for CE‑marked digital medical devices entering EU markets.​ EU‑backed projects such as DigitalHealthEurope and related initiatives continue to feed recommendations into EHDS implementation, standards and coordination, shaping the environment for HealthTech vendors selling into national systems.​

This Week in European HealthTech and MedTech: 19th December 2025

The role of Nelson Advisors in UK market entry strategies is defined by a highly specialised, nuanced, and holistic advisory model. The firm is not a generalist M&amp;A broker but a strategic partner exclusively focused on the HealthTech sector. Its value proposition is built on three pillars: &nbsp;&nbsp; Niche Specialisation: The exclusive focus on HealthTech and its sub-segments, especially high-growth areas like Healthcare AI and Cybersecurity, provides a profound understanding of a complex, regulated industry that generalist firms cannot match.Practitioner-Led Expertise: The "Founders for Founders" approach, combining entrepreneurial and corporate finance backgrounds, allows the firm to provide advice that is both financially astute and operationally empathetic, fostering a deeper level of trust and strategic alignment with founder-led companies.Holistic Strategic Framework: The "Build, Buy, Partner, Sell" framework guides clients through a comprehensive assessment of their strategic options, ensuring that a decision to enter the UK market is made in the context of long-term shareholder value and market dynamics. &nbsp; For North American and European companies considering a UK market entry, the implications of this analysis are clear. Nelson Advisors is particularly well-suited for companies seeking a partner who can provide strategic guidance on more than just a transaction.&nbsp; &nbsp;&nbsp; Nelson Advisor’s deep regulatory knowledge is invaluable for navigating the complexities of the UK and EU compliance landscape. Furthermore, for companies operating in the AI or cybersecurity spaces, a specialised partner with a proven track record is essential for accurately valuing assets and mitigating risks. In a market where a "flight to quality" is increasingly evident, Nelson Advisors LLP's qualitative leadership and specialised expertise offer a compelling alternative to larger, generalist firms, positioning it as a critical ally for achieving sustainable success in the UK HealthTech market.

Nelson Advisors

Blog

J.P. Morgan Annual Healthcare Conference 2026: Key predic...

10 Key Variables driving HealthTech and MedTech M&A valua...

This Week in European HealthTech and MedTech: 23rd Decemb...

'Founder Bankers' advising European HealthTech and MedTech

This Week in European HealthTech and MedTech: 19th Decemb...

Nelson Advisors' Role in UK HealthTech and MedTech Market...